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Steroid 21-hydroxylase deficiency accounts for about 95% of cases of congenital adrenal hyperplasia (CAH). Newborns are
currently being screened for the classical forms of this disease throughout the United States and in 12 other countries. As such,
it seems important to develop the best practice guidelines for treating not only infants and children, but affected adults as well.
This report gives a brief overview of the most recent expert opinion and clinical practice guidelines for CAH as formulated by The
Endocrine Society Task Force.
1. Introduction
The Endocrine Society, along with 6 sister medical societies
in North America and Europe, as well as a patient education
and support organization, recently sponsored the develop-
ment of an updated set of guidelines for clinicians treating
child and adult patients with congenital adrenal hyperplasia
(CAH) due to 21-hydroxylase deficiency [1]. The reader is
referred to brief [2] and comprehensive [3] reviews of this
disease for background. A “Consensus Statement” had been
published jointly by representatives of pediatric endocrine
societies in 2002 [4, 5], and the present Task Force made an
effort to include more information regarding adult patients.
In addition, the 2010 Endocrine Society Guideline had the
benefit of panel members who are experts in evidence based
medicine, specifically, systematic literature review and meta-
analysis. As readers may be aware, there are very few high
quality randomized, controlled clinical trials dealing with
CAH treatment. Notwithstanding this obstacle, the Task
Force combined the results of meta-analyses in two topical
and controversial areas of CAH treatment, with expert’s
opinions, tempered with valuable judgments to arrive at
the recommendations. The guidelines were reviewed and
approved sequentially by The Endocrine Society’s Clinical
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Guidelines Subcommittee and Clinical Affairs Core Commit-
tee, members responding to a web posting, The Endocrine
Society Council, and finally by representatives of each of
the cosponsoring sister medical societies. At each stage the
Task Force incorporated changes in response to written
comments. Thus, the document represents the collective
wisdom of a large and diverse group of practitioners.
The following is a summary of recommendations pre-
sented in each of ten areas of interest. A description of
the GRADE system for ranking the quality of medical
evidence is reviewed in [6]. In brief, “recommendations”
are relatively firmly held and graded “1,” whereas less well-
supported “suggestions” are graded “2.” The number of ⊕
symbols following recommendations and suggestions reflect
the strength of the evidence.
2. Newborn Screening
The Task Force believes that newborn screening for CAH
due to 21-hydroxylase deficiency should be incorporated
into all newborn screening programs (1|⊕⊕OO). Ideally, the
first-tier screening test, a 17-hydroxyprogesterone (17-OHP)
immunoassay, should be standardized to one type of assay.
At present most programs use DELFIA. We recommend
that norms be stratified by gestational age (1|⊕⊕OO),
rather than by birthweight [7]. Second-tier confirmatory
tests by liquid chromatography/tandem mass spectrometry
are recommended to improve CAH screening’s positive
predictive value [8], presently hovering around 1% for most
US programs. As of this paper, the throughput of tandem
mass spectrometry is not fast enough for this method to be
used as a primary screen. Each screening program, region, or
country should adopt specific protocols to deal with positive
newborn screens (1|⊕⊕OO).
3. Prenatal Treatment of CAH
Prenatal therapy to minimize virilization of affected female
fetuses in empiric protocols with arbitrary fixed doses of
dexamethasone administered from the mid-first trimester
have been in use for close to three decades [9, 10]. The lack
of adequately detailed and controlled long-term follow-up
studies on the offspring of treated pregnancies is disappoint-
ing. In the centers with the most experience, fewer than 50%
of mothers and offspring have responded to questionnaires
(Meyer-Bahlburg, H, personal communication). The Task
Force expressed concern about this, and about the fact
that, as presently practiced, 7 unaffected male fetuses must
be treated for each affected female. Numerous studies in
experimental animal models and retrospective studies of
human glucocorticoid (GC)-treated non-CAH pregnancies,
have revealed potential adverse effects (summarized in [11]).
For these reasons, prenatal therapy should be pursued
through protocols approved by Institutional Review Boards
at centers capable of collecting outcomes data on a suffi-
ciently large number of patients so that risks and benefits of
this treatment can be defined more precisely (2|⊕⊕OO). To
this end, data from multicenter studies with similar protocols
should be pooled. Noninvasive determination of fetal sex
from fetal cell-free DNA in the mother’s blood could help
avoid treatment of male fetuses. The latter technique is
widespread in Europe, but has not yet been approved for
commercial use in the United States. Additionally, it would
be of interest to determine whether the dexamethasone dose
could be reduced later in gestation to improve safety without
sacrificing efficacy.
4. Diagnosis of NCCAH/CAH after Infancy
An early morning (before 0800) baseline serum 17-OHP by
liquid chromatography/tandem mass spectrometry appears
to be the screening test of choice in symptomatic individ-
uals after infancy (1|⊕⊕OO). A screening serum 17-OHP
greater than 6 nmol/l or 200 ng/dl [12] warrants obtaining
a complete adrenocortical profile following cosyntropin
stimulation to differentiate 21-hydroxylase deficiency from
other enzyme defects and to make the diagnosis in borderline
cases (1|⊕⊕OO). Genotyping is now widely available and is
helpful when results of the adrenocortical profile following
cosyntropin stimulation test are equivocal, or for purposes
of genetic counseling (2|⊕OOO).
5. Medical Treatment of CAH in
Growing Patients
The GC of first choice for maintenance therapy of children
with CAH is hydrocortisone [13] in tablet form. For infants,
tablets may be crushed, weighed, and mixed with a small
amount of liquid and delivered immediately by medication
syringe, rather than from bulk suspension preparations that
deliver uneven doses (1|⊕⊕⊕O). It is recognized that pred-
nisolone and dexamethasone are sometimes useful in treat-
ing patients refractory to hydrocortisone [14], however, the
Task Force recommends against the routine chronic use of
long-acting potent GCs in growing patients (1|⊕⊕OO). All
patients with classic CAH should receive mineralocorticoid
(MC) supplementation in the form of oral fludrocortisone
and sodium chloride supplements in the newborn period
and early infancy, and as needed throughout life (1|⊕⊕OO).
GC dosage should be increased in stressful situations
such as febrile illness (>38.5◦C), gastroenteritis with dehy-
dration, surgery accompanied by general anesthesia, and
major trauma (1|⊕⊕OO). We recommend against the use
of increased GC doses in mental and emotional stress,
minor illness, and before physical exercise, as this would
greatly increase the frequency of supraphysiologic dosing
(1|⊕OOO). We also recommend against the use of stress
doses of GC in patients with nonclassic CAH unless their
adrenal function is suboptimal or iatrogenically suppressed
(1|⊕OOO). We suggest that patients who require treatment
always wear or carry medical identification indicating that
they have adrenal insufficiency (2|⊕OOO).
Patients should be regularly monitored for signs of
GC excess, inadequate androgen suppression in cases of
inadequate GC treatment, or hypertension with excess MC
and/or sodium (1|⊕⊕OO). We recommend monitoring
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treatment by consistently timed hormone measurements
(1|⊕OOO). Endogenous adrenal steroid secretion should
not be completely suppressed in order to avoid adverse
effects of overtreatment (1|⊕⊕OO). In addition to hormone
measurements, we suggest regular monitoring of height,
weight, and physical examination; annual bone age X-ray
assessment is also suggested after 2 years of age (2|⊕OOO).
6. Treatment of NCCAH in Childhood
Nonclassic CAH (NCCAH) is not generally considered an
absolute indication for glucocorticoid or mineralocorticoid
replacement therapy. Children diagnosed with NCCAH
should be offered treatment when they have inappropriately
early onset and rapid progression of pubarche or bone age.
Adolescent females with overt virilization or erratic menses
may also benefit from treatment (2|⊕⊕OO). Asymptomatic
individuals with NCCAH need not be treated (1|⊕⊕OO).
Moreover, previously treated NCCAH patients should be
given the option of discontinuing therapy when their
symptoms resolve (2|⊕⊕OO).
7. Complications of CAH
All GC-treated patients should be monitored for iatrogenic
Cushing syndrome (1|⊕⊕OO). Elements of the visit helpful
in this regard are the growth chart for height and weight
in children, distribution of body fat, presence of pigmented
striae, blood pressure measurements, and blood glucose
determinations. Since osteopenia and osteoporosis are rare in
pediatric CAH patients, routine evaluation of bone mineral
density is discouraged in children, but should be considered
in any patient who has been subjected to chronic high
doses of glucocorticoids or who has sustained fractures
(2|⊕OOO). Adrenal nodules have been identified more
frequently in CAH patients and carriers than in the general
population [15], however, adrenal imaging (generally CT
scans) ought to be reserved for those patients who have
an atypical clinical or biochemical course due to the high
radiation burden of frequent screening (2|⊕OOO). Males
with classic CAH should be periodically screened with
ultrasound for testicular adrenal rests [16]. The latter can
often be managed medically by more effectively suppressing
the pituitary-adrenal axis.
8. Feminizing Surgery
The vast majority of genetic females affected with classic
CAH have female gender identity and behavior, tomboyish
play and male occupational preferences notwithstanding
[17, 18]. In addition, most affected women can bear healthy
offspring, if desired [19]. This rationale is the basis for the
suggestion that severely virilized (Prader stage ≥ 3) females
be considered for clitoral and perineal reconstruction in
infancy. This type of surgery should only be performed by
experienced surgeons in centers with similarly experienced
pediatric endocrinologists, mental health professionals, and
social work services (2|⊕⊕OO). At present, the procedures
favored by pediatric urologists are neurovascular-sparing
clitoroplasty and vaginoplasty using total or partial uro-
genital mobilization [20] (2|⊕OOO). Continued long-term
outcome studies of early surgery are to be encouraged.
9. Alternative Therapies
Preservation of statural growth potential is an important goal
for clinicians caring for CAH children. Suboptimal height
outcomes are potentially related to late diagnosis and treat-
ment, overtreatment with glucocorticoids, or nonadherence
to the medical regimen. It is eminently possible to achieve
adult height within the normal range with standard steroid
therapy alone (mean height −1.0 SD corrected for parental
height among >1000 published cases [Muthusamy K et al.
JCEM, in press, 2010]). Thus, the Task Force recommends
against the use of alternative treatment approaches, for
example, growth hormone and/or treatment to delay puberty
or epiphyseal fusion for most children with CAH (1|⊕⊕OO).
Children with predicted height SD≤–2.25 may be considered
for such growth-promoting treatments in appropriately
controlled trials (2|⊕OOO). Further prospective, random-
ized, and carefully controlled studies would be helpful in
determining whether the use of growth-promoting drugs
increases adult height in patients with CAH (2|⊕OOO).
Unlike endogenous continuously variable cortisol secre-
tion, current glucocorticoid replacement therapy is given
between once and three times daily. It would therefore be
desirable to develop new treatment approaches that could
both minimize daily GC exposure and more closely mimic
the physiologic state. Recent research efforts along these lines
have included a long-acting oral form of hydrocortisone [21]
and use of continuous subcutaneous hydrocortisone infusion
by insulin pump [22].
Bilateral adrenalectomy has been considered in selected
individuals who have failed medical therapy, especially in
adult females with SW CAH and infertility [23]. In all
such cases, the risk for noncompliance with postoperative
replacement therapy must be evaluated prior to surgery. The
Task Force advises against routine adrenalectomy to treat
CAH (2|⊕OOO).
10. CAH in Adulthood
As in younger subjects, when the diagnosis of NCCAH is sus-
pected, screening may be done with an early morning serum
measurement of 17OHP by liquid chromatography and
tandem mass spectrometry. Menstruating women should
be screened in the early follicular phase of the menstrual
cycle [24]. If equivocal, the result should be confirmed by
performing a cosyntropin stimulation test before ordering
genotyping (1|⊕⊕OO). As discussed above, only individuals
with a significant degree of hyperandrogenism or those who
desire fertility need to be treated (2|⊕OOO). CAH women
should be screened for their gynecological history, and pelvic
examination should be performed beginning in adolescence.
Pelvic ultrasound should be reserved for CAH patients with
irregular menstrual cycles (2|⊕OOO).
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Whereas adult males with classic CAH should continue
their glucocorticoids indefinitely, men with NCCAH seldom
require treatment. Any CAH patient with impaired fertility
should consult a reproductive endocrinologist and/or fertil-
ity specialist (2|⊕⊕OO).
In the adult population, long-acting glucocorticoids such
as prednisolone and dexamethasone may be used judiciously
without concern about growth inhibition, but patients
should be monitored at least yearly for iatrogenic Cushing
syndrome. Clues to overtreatment include centripetal obe-
sity, striae, hypertension, glucose intolerance, and low bone
density.
Genetic counseling should be given to parents of known
CAH patients preconceptually, or at birth of a first CAH
child, and to affected adolescents at the transition to adult
care (1|⊕OOO). A multidisciplinary team consisting of
pediatric and adult endocrinologists, reproductive endocri-
nologists, gynecologists, and urologists is the ideal setting for
transitioning CAH patients to adult care (2|⊕OOO).
11. Pregnancy
Pregnant women with CAH are best followed jointly by
endocrinologists and obstetricians, while continuing their
prepregnancy doses of hydrocortisone/prednisolone and
fludrocortisone therapy. GC doses often need to be increased
during pregnancy, and should be adjusted before symptoms
and signs of GC insufficiency occur. The usual hormone
measurements to assess control are not informative during
pregnancy. Stress doses of hydrocortisone should be used
during labor and delivery. Dexamethasone should not be
given to pregnant women with CAH, if the mother is the
treatment target. This drug is not inactivated by placental 11-
hydroxysteroid dehydrogenase type 2, and as such may cause
fetal adrenal suppression (1|⊕⊕OO).
12. Mental Health
It is suggested that patients with CAH and psychosocial
problems associated with disorders of sexual development
be referred to mental health staff with specialized expertise
in managing such problems. Toward this goal, the Task
Force suggests the development, evaluation, and implemen-
tation of valid CAH-specific quality of life assessment tools
(2|⊕OOO).
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